Polymer-lipid microparticles for pulmonary delivery

Georgios K. Eleftheriadis; Melpomeni Akrivou; Nikolaos Bouropoulos; John Tsibouklis; Ioannis S Vizirianakis; Dimitrios G. Fatouros

doi:10.1021/acs.langmuir.7b03645

Polymer-lipid microparticles for pulmonary delivery

Georgios K. Eleftheriadis, Melpomeni Akrivou, Nikolaos Bouropoulos, John Tsibouklis, Ioannis S Vizirianakis, Dimitrios G. Fatouros

Institute of Life Sciences and Healthcare

Research output: Contribution to journal › Article › peer-review

251 Downloads (Pure)

Abstract

Towards engineering approaches that are designed to optimize the particle size, morphology and mucoadhesion behavior of the particulate component of inhaler formulations, this paper presents the preparation, physicochemical characterization and preliminary in vitro evaluation of multicomponent polymer-lipid systems that are based on “spray-drying engineered” α-lactose monohydrate microparticles. The formulations combine an active (budesonide) with a lung surfactant (dipalmitoylphosphatidylcholine) and with materials that are known for their desirable effects on morphology (polyvinyl-alcohol), aerosolization (L-leucine) and mucoadhesion (chitosan). The effect of the composition of formulations on the morphology, distribution and in vitro mucoadhesion profiles is presented along with “Calu-3 cell monolayers” data that indicate good cytocompatibility and also with simulated-lung-fluid data that are consistent with the therapeutically useful release of budesonide.

Original language	English
Pages (from-to)	3438-3448
Number of pages	11
Journal	Langmuir
Volume	34
Issue number	11
Early online date	27 Feb 2018
DOIs	https://doi.org/10.1021/acs.langmuir.7b03645
Publication status	Published - 20 Mar 2018

Access to Document

10.1021/acs.langmuir.7b03645

Polymer-lipid microparticles
This document is the Accepted Manuscript version of a Published Work that appeared in final form in Langmuir, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://pubs.acs.org/doi/10.1021/acs.langmuir.7b03645.
Accepted author manuscript (Post-print), 1.87 MB

http://pubs.acs.org/doi/10.1021/acs.langmuir.7b03645

Cite this

@article{61f1bec3fa114ebe9f16f136e22650ff,

title = "Polymer-lipid microparticles for pulmonary delivery",

abstract = "Towards engineering approaches that are designed to optimize the particle size, morphology and mucoadhesion behavior of the particulate component of inhaler formulations, this paper presents the preparation, physicochemical characterization and preliminary in vitro evaluation of multicomponent polymer-lipid systems that are based on “spray-drying engineered” α-lactose monohydrate microparticles. The formulations combine an active (budesonide) with a lung surfactant (dipalmitoylphosphatidylcholine) and with materials that are known for their desirable effects on morphology (polyvinyl-alcohol), aerosolization (L-leucine) and mucoadhesion (chitosan). The effect of the composition of formulations on the morphology, distribution and in vitro mucoadhesion profiles is presented along with “Calu-3 cell monolayers” data that indicate good cytocompatibility and also with simulated-lung-fluid data that are consistent with the therapeutically useful release of budesonide.",

author = "Eleftheriadis, {Georgios K.} and Melpomeni Akrivou and Nikolaos Bouropoulos and John Tsibouklis and Vizirianakis, {Ioannis S} and Fatouros, {Dimitrios G.}",

year = "2018",

month = mar,

day = "20",

doi = "10.1021/acs.langmuir.7b03645",

language = "English",

volume = "34",

pages = "3438--3448",

journal = "Langmuir",

issn = "0743-7463",

publisher = "American Chemical Society",

number = "11",

}

TY - JOUR

T1 - Polymer-lipid microparticles for pulmonary delivery

AU - Eleftheriadis, Georgios K.

AU - Akrivou, Melpomeni

AU - Bouropoulos, Nikolaos

AU - Tsibouklis, John

AU - Vizirianakis, Ioannis S

AU - Fatouros, Dimitrios G.

PY - 2018/3/20

Y1 - 2018/3/20

N2 - Towards engineering approaches that are designed to optimize the particle size, morphology and mucoadhesion behavior of the particulate component of inhaler formulations, this paper presents the preparation, physicochemical characterization and preliminary in vitro evaluation of multicomponent polymer-lipid systems that are based on “spray-drying engineered” α-lactose monohydrate microparticles. The formulations combine an active (budesonide) with a lung surfactant (dipalmitoylphosphatidylcholine) and with materials that are known for their desirable effects on morphology (polyvinyl-alcohol), aerosolization (L-leucine) and mucoadhesion (chitosan). The effect of the composition of formulations on the morphology, distribution and in vitro mucoadhesion profiles is presented along with “Calu-3 cell monolayers” data that indicate good cytocompatibility and also with simulated-lung-fluid data that are consistent with the therapeutically useful release of budesonide.

AB - Towards engineering approaches that are designed to optimize the particle size, morphology and mucoadhesion behavior of the particulate component of inhaler formulations, this paper presents the preparation, physicochemical characterization and preliminary in vitro evaluation of multicomponent polymer-lipid systems that are based on “spray-drying engineered” α-lactose monohydrate microparticles. The formulations combine an active (budesonide) with a lung surfactant (dipalmitoylphosphatidylcholine) and with materials that are known for their desirable effects on morphology (polyvinyl-alcohol), aerosolization (L-leucine) and mucoadhesion (chitosan). The effect of the composition of formulations on the morphology, distribution and in vitro mucoadhesion profiles is presented along with “Calu-3 cell monolayers” data that indicate good cytocompatibility and also with simulated-lung-fluid data that are consistent with the therapeutically useful release of budesonide.

U2 - 10.1021/acs.langmuir.7b03645

DO - 10.1021/acs.langmuir.7b03645

M3 - Article

SN - 0743-7463

VL - 34

SP - 3438

EP - 3448

JO - Langmuir

JF - Langmuir

IS - 11

ER -

Polymer-lipid microparticles for pulmonary delivery

Abstract

Access to Document

Fingerprint

Cite this